Skip to main content

Table 1 Main characteristics of the eligible studies

From: Prognostic value of YKL-40 in solid tumors: a meta-analysis of 41 cohort studies

Study Patients’ country No. of patients Tumor stagea Treatment methods Cutoff value Specimen type
Breast cancer
 Johansen 1995 [9] Denmark 41 Chemotherapy 207 μg/L Serum
 Jensen 2003 [21] Denmark 100 Metastatic disease (100) Chemotherapy 168 μg/L Serum
 Johansen 2003 [22] England 271 Surgery and chemotherapy and radiotherapy Serum
 Yamac 2008 [29] Turkey 45 I–III (62.2) Surgery and chemotherapy Serum
 Wang 2012 [38] China 120 TNM I–III (23.3) Surgery Serum
Gastrointestinal tumors
 Cintin 1999 [18] Denmark 603 Dukes’ staging A–D (53.4) Surgery 247 μg/L Serum
 Chang 2009 [30] America 52 II–III (–) Chemotherapy and radiotherapy Continuous variable Plasma
 Zhu 2012 [39] China 212 Chemoembolization 106 μg/L Serum
 Zhu 2012 [40] China 158 TNM I–IV (38.0) Surgery Continuous variable Serum
 Schultz 2013 [41] Denmark and Germany 103 Surgery; chemotherapy (not undergoing surgery) 116 μg/L Plasma
370
 Liu 2014 [43] China 86 UICC I–IV (44.2) Surgery and chemotherapy 216 μg/L Serum
 Tarpgaard 2014 [44] 32 Nordic centers 510 Metastatic disease (100) Chemotherapy Continuous variable Plasma
 Jensen 2016 [47] Denmark 162 Metastatic disease (100) Cetuximab and irinotecan Continuous variable Plasma
98
 Thongsom 2016 [50] Thailand 57 TNM I–IV (78.9) Surgery 100.7 μg/L Plasma
 Gramkow 2017 [52] Finland 457 Metastatic disease (100) Liver resection Serum
 Fuksiewicz 2018 [55] Poland 83 Surgery 44.6 μg/L Serum
Ovarian cancer
 Dehn 2003 [19] Denmark 73 I–IV (75.3) Chemotherapy 160 μg/L Plasma
 Høgdall 2003 [20] Denmark 47 III(100) Surgery 130 μg/L Plasma
 Høgdall 2009 [31] Denmark 76 I–IV (72.4) Surgery and chemotherapy Plasma
 Boisen 2016 [49] Denmark 140 FIGO I–IV (82.1) Bevacizumab Plasma
Lung cancer
 Johansen 2004 [23] Denmark 131 Limited and extended disease (55.0) Chemotherapy Serum
 Choi 2010 [34] Korea 39 IIIB–IV (100) Chemotherapy 165 μg/L Serum
 Thöm 2010 [35] Germany 189 III–IV (100) Chemotherapy 209 μg/L Serum
 Xu 2014 [46] China 120 Limited and extended disease (41.7) Chemotherapy 65.7 μg/L Serum
 Matsuo 2019 [57] Japan 50 III–IV (100) Anti-PD-1 inhibitor Plasma
Urologic neoplasms
 Brasso 2006 [24] Denmark 152 Metastatic disease (100) Endocrine therapy 104 μg/L Serum
 Johansen 2007 [27] Denmark 102 Total androgen ablation or parenteral estrogen Continuous variable Serum
 Tschirdewahn 2014 [45] Germany 101 T stage Ta–T4 (45.5) Surgery 90 μg/L Serum
 Vom Dorp 2016 [48] Germany 152 Stage pT1–T4 (40.1) Surgery 185 μg/L Serum
 Väänänen 2017 [54] Finland 82 Metastatic and non-metastatic disease (25.6) Surgery 120 μg/L Serum
 Darr 2018 [56] Germany 109 Metastatic disease(100) Chemotherapy 160 μg/L Serum
Melanoma
 Schmidt 2006 [25] Denmark 225 I–II (0) Surgery 124 μg/L Serum
 Schmidt 2006 [26] Denmark 110 IV (100) Chemotherapy and immunotherapy 124 μg/L Serum
 Krogh 2016 [51] Europe 299 Stage IIB and III (–) Untreated Continuous variable Serum
 Erturk 2017 [53] Turkey 112 chemotherapy and radiotherapy and immunotherapy 174.88 μgL Serum
Squamous cell carcinoma of the head and neck
 Roslind 2008 [28] Denmark 144 I–IV (55.6) Radiotherapy Serum
Multiple tumors
 Johansen 2009 [32] Denmark 1432 Localized disease and metastatic disease (40.8) Plasma
Cervical adenocarcinoma
 Mitsuhashi 2009 [33] Japan 37 I–IV (29.7) Surgery and chemoradiation 130 μg/L Serum
Glioblastoma
 Iwamoto 2011 [36] America 141 Surgery 98 μg/L Serum
 Bernardi 2012 [37] Italy 60 Astrocytoma
Grade IV (100)
Surgery and irradiation and chemotherapy Serum
 Gállego 2014 [42] France 111 Surgery 60 μg/L Plasma
  1. – not reported
  2. aTumor stage and proportion of advanced stage(%)